by Endo Australia Digital | Aug 3, 2026 | Endo medical, Endo news and media
Endometriosis Australia welcomes commitment to ongoing access to Zoladex Endometriosis Australia welcomes confirmation that Zoladex® (goserelin 3.6 mg) will remain available to Australian patients who rely on it, following AstraZeneca’s decision to supply the...
by Endo Australia Digital | Jul 29, 2026 | Endo podcast
Your Story Could Shape the Future of Endometriosis Care: Inside the NECST Registry Every person’s experience of endometriosis is different. That’s part of what makes it so hard to diagnose, so hard to treat, and so often misunderstood. But it’s also...
by Endo Australia Digital | Jun 11, 2026 | Endo stories
She Was Dismissed for 24 Years. Then They Found Endometriosis Everywhere When Pru first went to the doctor, to ask for help, she was 14. She was in pain. Severe, relentless pain. The kind that stops you from functioning, that leaves you exhausted, frightened, and...
by Endo Australia Digital | Jun 4, 2026 | Endo news and media
Endometriosis Australia calls for urgent action to protect access to essential treatment following Zoladex withdrawal Endometriosis Australia is deeply concerned by the announcement that Zoladex® (goserelin 3.6 mg) will be withdrawn from the Australian market later...
by Endo Australia Digital | Jun 2, 2026 | Endo medical
Medically induced menopause after treatment for endometriosis or adenomyosis Making decisions about treatment for endometriosis or adenomyosis can feel overwhelming, especially when treatments can cause side effects such as medically induced menopause. It’s natural to...
